Zealand Pharma has announced the launch of two Phase I clinical trials by its partner Boehringer Ingelheim to investigate a glucagon / GLP-1 agonist and an amylin analogue for the treatment of obesity and / or type 2 diabetes.

With a dual-acting mechanism, the glucagon / GLP-1 agonist triggers GLP-1 and glucagon receptors and is expected to provide better blood sugar and weight loss control.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The compound is partly based on the effects of a natural gut hormone called oxyntomodulin that is known to minimise food intake and improve energy expenditure.

Amylin is a pancreatic peptide hormone involved in a decrease in food intake and in postprandial plasma glucose levels regulation.

The long-acting amylin analogue compound is reported to have shown significant weight loss in preclinical obesity models.

See Also:

"We are proud that Boehringer Ingelheim has chosen to move these two novel analogues forward to Phase I."

Both compounds have been invented through a research collaboration between the firms, under which Boehringer Ingelheim funds the entire research, development and commercialisation activities.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Zealand Pharma executive vice-president, chief medical and development officer Adam Steensberg said: "We are proud that Boehringer Ingelheim has chosen to move these two novel analogues forward to Phase I.

“It demonstrates the quality of Zealand's approach in developing novel peptides for the potential benefit of millions of people needing adequate solutions for treating obesity and better treatment options for their diabetes.”

Both the randomised and double-blind Phase I trials will be conducted in Germany and will investigate the safety and tolerability of single ascending doses of the particular compound in healthy volunteers.

It is expected that the results from both trials will be available late next year.